Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes

Haematologica 2026 Open access

Read full text
Authors: Mahmood Aldapt, Yu‐Hung Wang, Kashish J. Shah, Mobachir El Kettani, James M. Foran, Mohamed A. Kharfan‐Dabaja, Hemant S. Murthy, Aref Al‐Kali, Mithun V. Shah, Hassan B. Alkhateeb, Antoine N. Saliba, William J. Hogan
+10 more Cecilia Arana Yi, Lisa Sproat, Nathan Punwani, Nandita Khera, Jeanne M. Palmer, Mark R. Litzow, Ayalew Tefferi, Naseema Gangat, Mrinal M. Patnaik, Talha Badar
DOI: 10.3324/haematol.2025.289268
Cited by: 0

Fields of Study & Subjects

Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment

Publication details

Journal / source
Haematologica
Volume
111
Issue
6
Pages
2159–2163
Publication date
8 January 2026
Language
EN